Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹2,293.30
20.00 (0.88%)
Medium VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹1.05L Cr
MID CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
19.4
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,836.8+24.9%
52W High₹2,494-8.0%
Current Price
₹2,293.30
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,834.64
Upper Circuit₹2,751.96
Reference Price
₹2,293.30
Investment Checklist
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹2117.0
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹2128.6
Trend: Price above all key MAs — strong uptrend
Volume divergence: Bearish (price up, volume down)
Composite score 43.78 (BUY) with 84.9% confidence
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
85%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend
EMA20
2273.71
EMA50
2283.55
EMA200
2167.24
Price Action
UPTREND
BULLISH
Higher Highs6
Higher Lows6
Lower Highs3
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹2307.95
₹2370.02
₹2494.00
Support (Below)
₹2238.01
₹2163.44
₹2107.40
₹2061.48
₹1985.48
Volume Analysis
TrendDECREASING
Change-37.60%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Recent MA Crossovers
10/20 Bearish Cross
4 days ago
SELL
Stop Loss Levels
Fixed Risk
1% Risk₹2270.37
3% Risk₹2224.50
5% Risk₹2178.64
7% Risk (Custom)
₹2132.77Technical Levels
1x ATR (Volatility)₹2248.25
2x ATR (Swing)₹2203.20
3x ATR (Trend)₹2158.15
Immediate Support₹2238.01
Moving Averages
EMA 9 (Short-term)₹2268.78
EMA 20 (Medium-term)₹2273.71
EMA 50 (Trend)₹2283.55
EMA 200 (Long-term)₹2167.24
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹5,618.6 Cr | ₹5,562.2 Cr | ₹6,163.8 Cr | ₹7,100.5 Cr |
| Net Profit | ₹855.2 Cr | ₹772.5 Cr | ₹1,219 Cr | ₹1,175.6 Cr |
| EPS | ₹18.75 | — | ₹26.70 | ₹25.74 |
| Operating Profit | ₹1,409.6 Cr | ₹1,353.8 Cr | ₹1,692.8 Cr | ₹1,950 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
| BIOCON | Biocon Limited | ₹419.00 | +0.73% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 25 Jul 2025 | Dividend - Rs 12 Per Share | DIVIDEND |
| 16 Jul 2024 | Dividend - Rs 8 Per Share | DIVIDEND |
| 14 Jul 2023 | Dividend - Rs 4 Per Share | DIVIDEND |
| 14 Jul 2022 | Dividend - Rs 4 Per Share | DIVIDEND |
| 27 Jul 2021 | Dividend - Rs 6.50 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for LUPIN
View All
positive
CNBC TV18 - Markets 3d ago
Bernstein backs Zydus, Lupin and Sun Pharma on innovation shift
Nandan Kulkarni, Director–India Healthcare & Senior Research Analyst at Bernstein, sees strong opportunities in CDMOs, specialty therapies, biosimilars and licensing deals. While favouring Zydus, Lupin and Sun Pharma, he remains cautious on Biocon and Mankind Pharma, and argues that India's shift from generics to innovation could drive the next phase of growth for the pharma industry.
ABSLNN50ETBIOCONBSLGOLDETFHCGHCG-REHEALTHCAREHEALTHYLUPINMANKINDONESOURCESPARCFinancial ServicesHealthcare
neutral
CNBC TV18 - Markets 5d ago
Lupin partners ERN to launch asthma and COPD treatment in Spain
Lupin has partnered Spain's ERN to launch Luforbec for asthma and COPD, extending its respiratory franchise in Europe as the drugmaker continues to build momentum across key global markets.
GLOBALLUPINMOMENTUMConsumer ServicesFinancial Services
NEWS
neutral
Business Standard - Markets 5d ago
Lupin launches Luforbec inhaler in Spain
In collaboration with ERN
LUPINHealthcare